• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by GoodRx Holdings Inc.

    5/30/24 4:29:52 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    DEFA14A 1 gdrx-fy23defa14asupplement.htm DEFA14A GDRX - FY23 DEFA 14A Supplement - S. Patterson
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the Securities
    Exchange Act of 1934 (Amendment No.     )
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    o
    Preliminary Proxy Statement
    o
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    o
    Definitive Proxy Statement
    x
    Definitive Additional Materials
    o
    Soliciting Material Pursuant to §240.14a-12
    GOODRX HOLDINGS, INC.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    x
    No fee required
    o
    Fee paid previously with preliminary materials
    o
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
    gdrxlogosmall.jpg
    SUPPLEMENT TO PROXY STATEMENT FOR
    ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, JUNE 6, 2024
    May 30, 2024
    To Our Stockholders:
    This supplement (this “Supplement”) relates to the Definitive Proxy Statement on Schedule 14A filed by
    GoodRx Holdings, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on April 25, 2024
    (the “Proxy Statement”) in connection with the Company’s 2024 Annual Meeting of Stockholders to be held on June 6,
    2024 (the “Annual Meeting”). Since the filing of the Proxy Statement, there have been developments regarding the
    Board of Directors of the Company (the “Board”). We are reaching out to you to describe these recent events and to
    supplement portions of the Proxy Statement, as set forth in this Supplement, which should be read in conjunction with
    the Proxy Statement in its entirety. Except as specifically discussed below, this Supplement does not otherwise
    modify or update any other disclosures in the Proxy Statement.
    Director Appointment
    On May 29, 2024, the Board, upon the recommendation of its Nominating and Corporate Governance
    Committee, elected Simon Patterson as a Class II director, effective immediately, to fill the vacancy on the Board
    created by the March 2024 resignation of Adam Karol. As a Class II director, Mr. Patterson’s term will expire at the
    Company’s 2025 Annual Meeting of Stockholders and until his successor is elected and qualified or until his earlier
    death, resignation or removal. The Board also appointed Mr. Patterson as a member of the Board’s Nominating and
    Corporate Governance Committee. The Board has determined that Mr. Patterson qualifies as “independent” under
    the rules of The Nasdaq Stock Market LLC. Mr. Patterson will not receive compensation for his service on the Board.
    Mr. Patterson, age 51, is a Managing Director at Silver Lake, a global technology investment firm (“Silver
    Lake”), which he joined in 2005. Prior to joining Silver Lake, Mr. Patterson was a member of the founding
    management team of Global Freight Exchange Limited, a logistics software company acquired by Descartes Systems
    Group, and worked in various management roles at the Financial Times, a leading news organization. Mr. Patterson
    serves on the board of directors of several private companies and is a Trustee and Vice Chairman of The Royal
    Foundation of The Prince and Princess of Wales and a member of Mark Carney’s Panel of Senior Advisors at
    Chatham House. Previously, Mr. Patterson served on the board of directors of various public companies, including
    Dell Technologies Inc., a leading technology company, from October 2013 to September 2023, and Tesco plc, a
    multinational grocery and general merchandise retailer, from April 2016 to June 2022, where he was a member of its
    audit committee. He also served as a Trustee of the Natural History Museum in London. Mr. Patterson holds an M.A.
    from King's College, Cambridge University and an M.B.A. from the Stanford University Graduate School of Business,
    where he was an Arjay Miller Scholar and received the Alexander Robichek Award for Finance. We believe Mr.
    Patterson is qualified to serve on the Board because he has significant financial and management expertise and
    extensive experience in operating, advising and investing in technology and technology-enabled companies.
    The Company is party to that certain Stockholders Agreement, dated as of September 22, 2020 (the
    “Stockholders Agreement”), by and among the Company, SLP Geology Aggregator, L.P. (with certain affiliate
    stockholders, the “Silver Lake Stockholders”), an entity affiliated with Silver Lake, and certain other stockholders of
    the Company (collectively, together with the Silver Lake Stockholders, the “Sponsor Stockholders”), pursuant to which
    the Company granted each Sponsor Stockholder certain board designation rights subject to such Sponsor
    Stockholder’s ownership of specified percentages of the Company’s common stock. The Silver Lake Stockholders did
    not exercise their right under the Stockholders Agreement to fill the vacancy created by Adam Karol’s resignation and
    retain such right to designate one additional director. As discussed above, the Board’s Nominating and Corporate
    Governance Committee recommended, and the Board approved, the appointment of Mr. Patterson to fill the Class II
    vacancy. Except for the applicable matters regarding SLP Geology Aggregator, L.P. and its affiliates disclosed in the
    Company’s most recent Definitive Proxy Statement, filed with the SEC on April 25, 2024, there are no transactions in
    which the Company is a party and in which Mr. Patterson has a material interest subject to disclosure under Item
    404(a) of Regulation S-K.
    Mr. Patterson has entered into the Company’s standard indemnification agreement for directors and officers,
    the form of which was previously filed by the Company as Exhibit 10.1 to the Registration Statement on Form S-1/A
    (File No. 333-248465) initially filed by the Company with the SEC on September 14, 2020.
    Mr. Patterson does not beneficially own any shares of our Class A common stock or Class B common stock.
    Committees of the Board
    Following Mr. Patterson’s election to the Board, the current members of each of the Board’s standing
    committees are as set forth in the following chart:
    Name
    Audit
    Compensation
    Compliance
    Nominating
    and Corporate
    Governance
    Christopher Adams
    X
    Chair
    Trevor Bezdek
    X
    X
    Julie Bradley
    Chair
    Kelly J. Kennedy1
    X
    Gregory Mondre2
    Chair
    Simon Patterson3
    X
    Agnes Rey-Giraud
    X
    Chair
    _________________________________
    (1)Ms. Kennedy was appointed to the Board and its Audit Committee, effective December 21, 2023.
    (2)Mr. Mondre stepped down as a member of the Nominating and Corporate Governance Committee, effective July 24, 2023.
    (3)Mr. Patterson was appointed to our Nominating and Corporate Governance Committee, effective May 29, 2024.
    Board Diversity Matrix (as of May 29, 2024)
    Total Number of Directors
    9
    Female
    Male
    Non-Binary
    Did Not
    Disclose
    Gender
    Part I Gender Identity
        Directors
    3
    6
    —
    —
    Part II Demographic Background
        African American or Black
    —
    —
    —
    —
        Alaskan Native or Native American
    —
    —
    —
    —
        Asian
    —
    1
    —
    —
        Hispanic or Latinx
    —
    —
    —
    —
        Native Hawaiian or Pacific Islander
    —
    —
    —
    —
        White
    3
    5
    —
    —
        Two or More Races or Ethnicities
    —
    —
    —
    —
        LGBTQ+
    1
        Did Not Disclose Demographic Background
    —
    Impact on Voting at the Annual Meeting
    You are not being asked to vote on or ratify the appointment of Mr. Patterson at the Annual Meeting. As a Class
    II director, Mr. Patterson is not a nominee for election at the Annual Meeting. Accordingly, this Supplement does not
    change the proposals to be voted on at the Annual Meeting or the recommendations of the Board with respect to such
    proposals, in each case, as described in the Proxy Statement. If you have already submitted your proxy, or voted by
    telephone or Internet, you do not need to take additional action unless you wish to change your vote. If you wish to
    change your vote, the Proxy Statement contains information on how to change your vote. The form of proxy included
    in the Company’s Proxy Statement remains valid, and no new proxy cards are being distributed.
    Whether or not you attend the Annual Meeting, it is important that your shares be represented and voted at the
    Annual Meeting. Thank you for your support.
    By Order of the Board of Directors,
    screenshot2023-06x26104911.jpg
    Gracye Cheng
    Secretary
    Santa Monica, California
    Get the next $GDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    1/22/2026$2.75Buy → Hold
    Jefferies
    12/9/2025$3.00Underweight
    Barclays
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

    Brief Summary: GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer's essential brand medications spanning women's health, arthritis, and more By unifying pricing, pharmacy enablement, and a trusted consumer experience, GoodRx enables pharma manufacturers to rapidly deploy and scale emerging pricing models with minimal operational lift GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on T

    2/5/26 7:44:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale

    Independent assessment validates GoodRx's continued leadership in cybersecurity and data protection GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its 2026 certification status for HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services (AWS). This certification shows continuous dedication to GoodRx's prior HITRUST achievement and underscores the company's ongoing commitment to safeguarding sensitive healthcare information. The HITRUST i1 Certification demonstrates that GoodRx has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls

    2/2/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

    GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., to offer eligible co

    2/2/26 8:01:00 AM ET
    $GDRX
    $SXTP
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 5,215 shares, increasing direct ownership by 5% to 172,923 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    2/9/26 5:49:36 PM ET
    $GDRX
    EDP Services
    Technology

    Director Wagner Scott converted options into 31,394 shares, increasing direct ownership by 17% to 216,663 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    1/21/26 5:20:35 PM ET
    $GDRX
    EDP Services
    Technology

    Officer Barnes Wendy Lynn converted options into 665,302 shares and covered exercise/tax liability with 237,309 shares (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    1/15/26 5:19:15 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    12/12/25 4:26:49 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:31:17 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:23:32 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology